

**Complete case analysis - Table 1.** Baseline characteristics of participants with complete data when outcome is defined by perceived pain at 6-month follow-up. Chronic pain (N = 67) was defined by the presence of pain (NRS  $\geq$  1) and recovery by the absence of pain (N = 29, NRS=0) at six-month follow up.

Characteristic	Recovered (N = 29)	Chronic pain (N = 67)	$P_{FDR}$ value
Gender: Female (%)	48.2	55.2	0.88
Previous history of LBP: No (%)	28.6	21.2	0.86
BDNF genotype: AA/AG (%)	31.0	38.8	0.86
Cultural diversity: No (%)	53.6	59.1	0.95
L3 map volume (cm <sup>2</sup> )	9.6 (3.8)	7.9 (4.0)	0.22
L5 map volume (cm <sup>2</sup> )	7.8 (2.6)	7.9 (3.9)	0.96
Log-transformed N <sub>80</sub> SEP area ( $\mu$ V)	-1.6 (1.3)	-3.2 (1.4)	<b>&lt; 0.001</b>
Log-transformed N <sub>150</sub> SEP area ( $\mu$ V)	-1.6 (1.2)	-3.0 (1.4)	<b>&lt; 0.001</b>
Age (years) <sup>§</sup>	33.9 (11.9)	42.1 (16.4)	<b>0.02</b>
Socioeconomic status (SEIFA score)	1023.7 (51.3)	1021.7 (64.5)	0.96
BDNF serum concentration (pg/mL)	48189.3 (11343.6)	54030.1 (14462.4)	0.22
Log-transformed CRP (pg/mL)	14.2 (1.3)	14.8 (1.4)	0.22
TNF (pg/mL)	6.88 (1.8)	7.8 (2.0)	0.16
PCS score <sup>§</sup>	6.0 (7.1)	12.5 (10.9)	<b>&lt; 0.01</b>
DASS-21 score <sup>§</sup>	8.4 (7.5)	23.8 (21.0)	<b>&lt; 0.001</b>
PSEQ score <sup>§</sup>	52.5 (8.5)	44.8 (12.7)	<b>&lt; 0.01</b>
Local sensitivity (kPa)	943.0 (367.1)	835.0 (361.3)	0.31
Distal sensitivity (kPa)	641.3 (269.0)	638.5 (216.6)	0.96

Variable means were compared between non-recovered and recovered low back pain participants using t tests (continuous variable) or  $X^2$  tests (categorical variables).

<sup>§</sup> Welch's t test was performed.

Statistically significant values are in bold font

Continuous data described as pooled mean  $\pm$  pooled SD. Categorical data described as percent.

AA/AG - G allele encodes Val, A allele encodes Met; BDNF – brain derived neurotrophic factor; CRP - C-reactive protein; DASS – depression, anxiety, stress subscale; FDR – false discover rate; LBP – low back pain; PCS – pain catastrophizing scale; PSEQ – pain self-efficacy questionnaire; TNF- $\alpha$  - tumor necrosis factor.

**Complete case analysis - Table 2.** Baseline characteristics of participants with complete data when outcome is defined by disability. Chronic disability (N = 35) was defined by RMDQ  $\geq$  3 and recovery by RMDQ score of  $\leq$  2 (N = 61) at six-month follow up.

Characteristic	Recovered (N = 61)	Chronic disability (N = 35)	$P_{\text{FDR}}$ value
Gender: Female (%)	55.7	49.0	0.71
Previous history of LBP: No (%)	26.7	17.6	0.65
BDNF genotype: AA/AG (%)	41.0	28.6	0.52
Cultural diversity: No (%)	55.0	61.8	0.71
L3 map volume (cm <sup>2</sup> )	9.3 (4.0)	6.6 (3.3)	<b>0.03</b>
L5 map volume (cm <sup>2</sup> )	8.3 (3.3)	6.9 (3.9)	0.28
Log-transformed N <sub>80</sub> SEP area ( $\mu$ V)	-2.4 (1.5)	-3.2 (1.5)	0.10
Log-transformed N <sub>150</sub> SEP area ( $\mu$ V)	-2.4 (1.5)	-2.85 (1.47)	0.34
Age (years) <sup>§</sup>	36.6 (13.9)	44.9 (17.0)	0.06
Socioeconomic status (SEIFA score)	1019.2 (59.6)	1027.8 (62.5)	0.65
BDNF serum concentration (pg/mL)	50573.7 (13232.0)	55156.8 (14449.8)	0.34
Log-transformed CRP (pg/mL)	14.4 (1.3)	14.9 (1.4)	0.29
TNF (pg/mL)	7.40 (2.0)	7.8 (1.9)	0.65
PCS score <sup>§</sup>	8.0 (8.6)	15.0 (11.6)	<b>0.01</b>
DASS-21 score <sup>§</sup>	14.0 (16.0)	28.2 (21.6)	<b>0.01</b>
PSEQ score <sup>§</sup>	50.6 (9.6)	40.9 (13.6)	<b>&lt; 0.01</b>
Local sensitivity (kPa)	854.9 (352.5)	887.8 (388.2)	0.71
Distal sensitivity (kPa)	641.4 (254.2)	635.9 (193.4)	0.91

Variable means were compared between non-recovered and recovered low back pain participants using t tests (continuous variable) or  $X^2$  tests (categorical variables).


<sup>§</sup> Welch's t test was performed.

Statistically significant values are in bold font


Continuous data described as mean  $\pm$  SD. Categorical data described as percent.

AA/AG - G allele encodes Val, A allele encodes Met; BDNF – brain derived neurotrophic factor; CRP - C-reactive protein; DASS – depression, anxiety, stress subscale; FDR – false discover rate; LBP – low back pain; PCS – pain catastrophizing scale; PSEQ – pain self-efficacy questionnaire; TNF- $\alpha$  - tumor necrosis factor.


**Complete case analysis - Figure 1.** Violin plots displaying the log-transformed distribution of baseline primary ( $N_{80}$ ) and secondary ( $N_{150}$ ) sensory evoked potential area under the curve mean amplitude ( $\mu V$ ) values, divided into those who recovered from their episode of acute LBP and those who developed **chronic pain** ( $NRS \geq 1$ ) at 6-months follow up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10<sup>th</sup> and 90th percentiles (lines outside the box). Raw values were log-transformed prior to analysis.




**Complete case analysis - Figure 2.** Violin plots displaying the log-transformed distribution of baseline primary ( $N_{80}$ ) and secondary ( $N_{150}$ ) sensory evoked potential area under the curve mean amplitude ( $\mu V$ ) values, divided into those who recovered from their episode of acute LBP and those who developed **chronic disability** ( $RMDQ \geq 3$ ) at 6-months follow up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10<sup>th</sup> and 90th percentiles (lines outside the box). Raw values were log-transformed prior to analysis.



**Complete case analysis - Figure 3.** Violin plots displaying the distribution of baseline map volume (cm<sup>2</sup>) from the L3 and L5 electromyographic recording sites, divided into those who recovered from their episode of acute LBP and those who developed **chronic pain** (NRS  $\geq 1$ ) at six-month follow-up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10<sup>th</sup> and 90th percentiles (lines outside the box).



**Complete case analysis - Figure 4.** Violin plots displaying the distribution of baseline map volume (cm<sup>2</sup>) from the L3 and L5 electromyographic recording sites, divided into those who recovered from their episode of acute LBP and those who developed **chronic disability** (RMDQ  $\geq 3$ ) at six-month follow-up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10<sup>th</sup> and 90th percentiles (lines outside the box).



**Complete case analysis - Table 3.** Adjusted and unadjusted linear regression models, including only complete cases, to test the effects of baseline sensorimotor cortex activity on pain intensity and RMDQ score at six-month follow-up.

Outcome	Model	Exposure	B (95% CI)	P <sub>FDR</sub>
Pain Intensity	Unadjusted	Log-transformed N <sub>80</sub> SEP area	-0.58 (-0.85, -0.31)	< <b>0.001</b>
		Log-transformed N <sub>150</sub> SEP area	-0.54 (-0.83, -0.25)	< <b>0.01</b>
		L3 map volume	-0.18 (-0.30, -0.06)	<b>0.01</b>
		L5 map volume	-0.06 (-0.20, 0.08)	0.41
	Adjusted <sup>1</sup>	Log-transformed N <sub>80</sub> SEP area	-0.14 (-0.55, 0.26)	0.63
		Log-transformed N <sub>150</sub> SEP area	-0.23 (-0.63, 0.17)	0.49
		L3 map volume	-0.16 (-0.35, 0.02)	0.32
		L5 map volume	-0.03 (-0.22, 0.17)	0.77
RMDQ score	Unadjusted	Log-transformed N <sub>80</sub> SEP area	-0.42 (-1.02, 0.17)	0.36
		Log-transformed N <sub>150</sub> SEP area	-0.33 (-0.96, 0.30)	0.41
		L3 map volume	-0.18 (-0.45, 0.09)	0.36
		L5 map volume	0.06 (-0.24, 0.37)	0.69
	Adjusted <sup>1</sup>	Log-transformed N <sub>80</sub> SEP area	-0.42 (-1.28, 0.45)	0.44
		Log-transformed N <sub>150</sub> SEP area	-0.62 (-1.47, 0.23)	0.29
		L3 map volume	-0.46 (-0.88, -0.04)	0.13
		L5 map volume	-0.11 (-0.56, 0.35)	0.63

<sup>1</sup> Adjusted for predisposing factors, blood biomarkers, psychological variables and sensitisation.

Statistically significant values are in bold font

B – unstandardized beta coefficient, CI – confidence interval, FDR – false discovery rate, SEP – somatosensory evoked potential

**Complete case analysis - Table 4.** Adjusted and unadjusted logistic regression models, including only complete cases, to test the effects of baseline sensorimotor activity on chronic pain and chronic disability at six-month follow-up.

Outcome	Model	Exposure	OR (95% CI)	$P_{\text{FDR}}$	E-Value	E CI
Chronic pain <sup>&amp;</sup>	Unadjusted	Log-transformed N <sub>80</sub> SEP area	2.08 (1.52, 3.03)	< <b>0.001</b>	2.24	1.76
		Log-transformed N <sub>150</sub> SEP area	2.04 (1.45, 2.94)	< <b>0.001</b>	2.21	1.70
		L3 map volume <sup>n.b.</sup>	1.11 (0.98, 1.28)	0.15	1.29	1.00
		L5 map volume	0.99 (0.85, 1.15)	0.91	1.08	1.00
	Adjusted <sup>1</sup>	Log-transformed N <sub>80</sub> SEP area	3.45 (1.30, 14.29)	0.08	3.12	1.54
		Log-transformed N <sub>150</sub> SEP area	7.14 (2.04, 100.00)	0.07	4.79	2.21
		L3 map volume <sup>n.b.</sup>	1.16 (0.93, 1.49)	0.23	1.37	1.00
		L5 map volume	1.12 (0.67, 2.00)	0.61	1.31	1.00
Chronic disability <sup>#</sup>	Unadjusted	Log-transformed N <sub>80</sub> SEP area	1.37 (1.03, 1.85)	0.07	1.62	1.14
		Log-transformed N <sub>150</sub> SEP area	1.22 (0.92, 1.67)	0.18	1.44	1.00
		L3 map volume <sup>n.b.</sup>	1.25 (1.06, 1.52)	0.04	1.48	1.21
		L5 map volume	1.14 (0.98, 1.35)	0.15	1.33	1.00
	Adjusted <sup>1</sup>	Log-transformed N <sub>80</sub> SEP area	2.00 (0.99, 5.00)	0.22	2.18	1.00
		Log-transformed N <sub>150</sub> SEP area	1.69 (0.93, 3.45)	0.22	1.93	1.00
		L3 map volume <sup>n.b.</sup>	1.16 (0.93, 1.56)	0.23	1.37	1.00
		L5 map volume	1.45 (0.93, 3.70)	0.23	1.70	1.00

<sup>&</sup> Chronic pain in this logistic model was defined as NRS score  $\geq 1$  at 6-month follow up.

<sup>#</sup> Chronic disability in this logistic model was defined as RMDQ score  $\geq 3$  at 6-month follow up.

<sup>1</sup> Adjusted for predisposing factors, blood biomarkers, psychological variables and sensitisation.

<sup>n.b.</sup> L3 map volume logistic regression models were not adequately powered to detect a meaningful effect. Therefore, we controlled for age, DASS, TNF- $\alpha$  and local PPT, a single variable from each confounder category. Despite this, no meaningful effects were observed, therefore this is unlikely to impact study conclusions.

Statistically significant values are in bold font

CI – confidence interval; DASS – depression, anxiety, stress subscale; FDR – false discovery rate; OR – odds ratio; PPT – pressure pain threshold; SEP – somatosensory evoked potential; TNF – tumor necrosis factor.